ClinicalTrials.gg
CompletedNCT02640664RainbowExtUpdated Feb 13, 2023Results posted

Rainbow Extension Study

A Phase 3 interventional study of Ranibizumab in Retinopathy of Prematurity (ROP), sponsored by Novartis Pharmaceuticals. Completed at 73 sites in 24 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2023-02-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
6 Months to 5 Years
Sex
All
01

Study summary

The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)

Read the detailed description

This was a multicenter, open-label extension study where the Visual Acuity (VA) assessment at the child's 5th birthday visit was performed. The study had 2 distinct periods (Epochs). Treatment with study ranibizumab (either as retreatment after ranibizumab had already been injected in the same eye or as switch ranibizumab treatment from study laser therapy administered in the core study) was permitted for eligible eyes with recurrence/worsening of ROP up to and including Week 40 from the baseline visit in the core study (Epoch 1). The remainder of the extension study up to the 5th birthday visit (Epoch 2) was observational, with no study treatment planned to be administered.

In the core study, patients were randomized to 1 of the 3 treatment arms (ranibizumab 0.2 mg, ranibizumab 0.1 mg, and laser). Treatment arm assignment and patient identifier in the extension study remained the same as in the core study.

02

Conditions studied

  • Retinopathy of Prematurity (ROP)

Keywords

  • open-label,
  • long-term,
  • extension study,
  • intravitreal ranibizumab,
  • laser ablation therapy,
  • retinopathy of prematurity,
  • preterm infants,
  • RAINBOW
03

In context

Retinopathy of Prematurity

169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.

This study's enrollment of 180 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.

Browse Retinopathy of Prematurity studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed from parent(s) or legal guardian(s), in compliance with local requirements
  • The patient successfully completed the core study H2301, as defined by providing assessments at the Visit 112 (the last scheduled visit in the core study) or, if appropriate, at the last of the additional assessment visits as per protocol in H2301, whichever was latest
  • The patient received study treatment in both eyes at baseline of study H2301

Exclusion criteria

Exclusion Criteria:

  • Patient had a medical condition or personal circumstance which precluded study participation or compliance with study procedures, as assessed by the Investigator
  • Patient had been discontinued from the core study H2301 at any time
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.2 mg

    1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 0.1 mg

    1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required

    Drug: Ranibizumab

  • No intervention
    Laser therapy

    Laser therapy

Interventions

  • 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required

06

What researchers measure

Primary outcomes

  1. Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms

    The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The better-seeing eye was defined as the eye with the higher ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the right eye was assigned as the better-seeing eye.

    Time frame: at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)

Secondary outcomes

  1. Number of Participants With Ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship by Preferred Term

    Number of participants with ocular AEs starting during the core study and ongoing at extension baseline, or starting on/after extension baseline were reported.

    Time frame: throughout the study, approximately 5 years

  2. Number of Participants With Non-ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship (Greater Than or Equal to 3% in Any Arm) by Preferred Term

    Number of participants with non-ocular adverse events regardless of study treatment or procedure relationship (greater than or equal to 3% in any arm) by preferred term were reported.

    Time frame: throughout the study, approximately 5 years

  3. Visual Acuity (VA) of the Worse-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms

    The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The worse-seeing eye was the eye with a lower ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the left eye was assigned as the worse-seeing eye.

    Time frame: at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)

  4. Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 40 Weeks Post Core Baseline Visit

    The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease.

    Time frame: at 40 weeks post core baseline visit

  5. Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 52 Weeks Post Core Baseline Visit

    The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease.

    Time frame: at 52 weeks post core baseline visit

  6. Number of Participants With Absence of All Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit

    The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula

    Time frame: at or before 40 weeks post baseline visit

  7. Number of Participants With Absence of All Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit

    The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula

    Time frame: at or before the participant's fifth birthday visit (up to maximum 5 years and 4 months post core baseline visit)

  8. Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit

    Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis

    Time frame: at or before 40 weeks post baseline visit

  9. Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit

    Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula

    Time frame: at or before the participant's fifth birthday visit (up to maximum 5 years and 4 months post core baseline visit)

  10. Number of Participants With Absence of All Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit

    The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula

    Time frame: at or before participant's 2 years corrected age visit (up to 2 years and 4 months post core baseline visit)

  11. Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit

    Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula

    Time frame: at or before participant's 2 years corrected age visit (up to 2 years and 4 months post core baseline visit)

  12. Number of Participants With Recurrence of ROP up to 40 Weeks Post Baseline Visit in the Core Study

    Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence.

    Time frame: up to 40 weeks post baseline visit in the core study

  13. Number of Participants With Recurrence of ROP up to 52 Weeks Post Baseline Visit in the Core Study

    Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence. Beyond Week 40, participants did not receive any study intervention and no new data was collected after 40 weeks post core baseline visit.

    Time frame: up to 52 weeks post baseline visit in the core study

  14. Number of Ranibizumab Injections Received Per Participant Over the Whole Safety Observation Period

    Number of ranibizumab injections received in the treatment of participants with ROP up to and including 40 weeks post baseline visit in the core study were reported.

    Time frame: up to and including 40 weeks post baseline visit in the core study

  15. Refraction Status: Summary of Participants at Participant's 2 Years Corrected Age

    Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years corrected age

    Time frame: at participant's 2 years corrected age (maximum 2 years and 4 months post core baseline visit)

  16. Refraction Status: Summary of Participants at the Participant's Fifth Birthday Visit

    Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years' corrected age

    Time frame: at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)

  17. Change From Baseline in Weight

    Subject´s weight was reported to evaluate the physical development.

    Time frame: Baseline of the core study, at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit) and at the subjects' fifth birthday (maximum 5 years and 4 months post core baseline visit)

  18. Change From Baseline in Head Circumference

    Subject´s head circumference was reported to evaluate the physical development.

    Time frame: Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)

  19. Change From Baseline in Sitting Diastolic Blood Pressure

    Subject´s Sitting Diastolic Blood Pressure was reported to evaluate the physical development.

    Time frame: Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)

  20. Change From Baseline in Sitting Systolic Blood Pressure

    Subject´s Sitting Systolic Blood Pressure was reported to evaluate the physical development.

    Time frame: Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)

  21. Number of Participants With the Summary of Respiratory Function Status

    Number of participants with respiratory function status was reported

    Time frame: at the participants' fifth birthday visit (maximum 5 years and 4 months post core baseline visit)

  22. Number of Participants With Hearing Impairment of Any Type

    Number of participants with hearing function status was reported

    Time frame: at the participants' fifth birthday visit (maximum 5 years and 4 months post core baseline visit)

  23. Duration of Hospitalization

    Duration of hospitalization (from birth to first hospital discharge home) was reported to evaluate the health status of the subject

    Time frame: From baseline of the core study up to 5 years and 4 months post core baseline visit

  24. Weight at the Time of First Hospital Discharge

    Weight (gram) at the time of first hospital discharge was reported to evaluate the health status of the subject

    Time frame: From baseline of the core study up to 5 years and 4 months post core baseline visit

07

Results

Posted Feb 13, 2023

Participant flow

Study was carried out in Austria (2), Belgium (2), Croatia (1), Czech Republic (3), Denmark (1), Egypt (1), Estonia (1), France (2), Germany (1), Greece (3), Hungary (2), India (6), Italy (4), Japan (16), Lithuania (1), Malaysia (2), Romania (3), Russian Federation (5), Saudi Arabia (1), Slovakia (1), Taiwan (2), Turkey (3), United Kingdom (2), United States of America (9)

Epoch 1
Participant flow — Epoch 1
MilestoneRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Started616554
Completed606553
Not completed101
Withdrew: Withdrawal of informed consent100
Withdrew: Death001
Epoch 2
Participant flow — Epoch 2
MilestoneRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Started606553
Completed545547
Not completed6106
Withdrew: Withdrawal of informed consent342
Withdrew: Subject/guardian decision022
Withdrew: Lost to follow-up341
Withdrew: Death001

Outcome measures

PrimaryVisual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms

The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The better-seeing eye was defined as the eye with the higher ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the right eye was assigned as the better-seeing eye.

Time frame:
at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Reported as:
Least squares mean · Score on a scale
Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms
Score on a scaleRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms66.8 ± 1.9564.6 ± 2.0062.1 ± 2.18
Statistical analysis
  • Ranibizumab 0.2 mg vs Laser Therapy · ANOVA · Mean difference (net): 4.7 · 95% CI -1.1 to 10.5
  • Ranibizumab 0.1 mg vs Laser Therapy · ANOVA · Mean difference (net): 2.5 · 95% CI -3.4 to 8.3
  • Ranibizumab 0.2 mg vs Ranibizumab 0.1 mg · ANOVA · Mean difference (net): 2.2 · 95% CI -3.3 to 7.8
SecondaryNumber of Participants With Ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship by Preferred Term

Number of participants with ocular AEs starting during the core study and ongoing at extension baseline, or starting on/after extension baseline were reported.

Time frame:
throughout the study, approximately 5 years
Reported as:
Count of participants · Participants
Number of Participants With Ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship by Preferred Term
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship by Preferred Term192622
SecondaryNumber of Participants With Non-ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship (Greater Than or Equal to 3% in Any Arm) by Preferred Term

Number of participants with non-ocular adverse events regardless of study treatment or procedure relationship (greater than or equal to 3% in any arm) by preferred term were reported.

Time frame:
throughout the study, approximately 5 years
Reported as:
Count of participants · Participants
Number of Participants With Non-ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship (Greater Than or Equal to 3% in Any Arm) by Preferred Term
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Non-ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship (Greater Than or Equal to 3% in Any Arm) by Preferred Term465346
SecondaryVisual Acuity (VA) of the Worse-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms

The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The worse-seeing eye was the eye with a lower ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the left eye was assigned as the worse-seeing eye.

Time frame:
at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Reported as:
Least squares mean · Score on a scale
Visual Acuity (VA) of the Worse-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms
Score on a scaleRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Visual Acuity (VA) of the Worse-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms60.2 ± 2.9553.8 ± 3.0552.2 ± 3.30
Statistical analysis
  • Ranibizumab 0.2 mg vs Laser Therapy · ANOVA · Mean difference (net): 8.0 · 95% CI -0.8 to 16.7
  • Ranibizumab 0.1 mg vs Laser Therapy · ANOVA · Mean difference (net): 1.6 · 95% CI -7.3 to 10.5
  • Ranibizumab 0.2 mg vs Ranibizumab 0.1 mg · ANOVA · Mean difference (net): 6.4 · 95% CI -2.0 to 14.8
SecondaryNumber of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 40 Weeks Post Core Baseline Visit

The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease.

Time frame:
at 40 weeks post core baseline visit
Reported as:
Count of participants · Participants
Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 40 Weeks Post Core Baseline Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Absence of active ROP at 40 weeks post core baseline visit555846
Absence of vessel dilatation555846
Absence of extra-retinal vessels575947
SecondaryNumber of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 52 Weeks Post Core Baseline Visit

The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease.

Time frame:
at 52 weeks post core baseline visit
Reported as:
Count of participants · Participants
Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 52 Weeks Post Core Baseline Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 52 Weeks Post Core Baseline Visit586349
SecondaryNumber of Participants With Absence of All Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit

The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula

Time frame:
at or before 40 weeks post baseline visit
Reported as:
Count of participants · Participants
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit596147
SecondaryNumber of Participants With Absence of All Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit

The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula

Time frame:
at or before the participant's fifth birthday visit (up to maximum 5 years and 4 months post core baseline visit)
Reported as:
Count of participants · Participants
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit596147
SecondaryNumber of Participants With Absence of Individual Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit

Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis

Time frame:
at or before 40 weeks post baseline visit
Reported as:
Count of participants · Participants
Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Absence of substantial temporal retinal vessel596349
Absence of Retrolental membrane obscuring the view of the posterior pole606553
Absence of posterior retinal fold involving the macula596551
Absence of retinal detachment involving the macula606351
Absence of retinal detachment not involving the macula606250
Absence of pre-retinal fibrosis586049
SecondaryNumber of Participants With Absence of Individual Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit

Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula

Time frame:
at or before the participant's fifth birthday visit (up to maximum 5 years and 4 months post core baseline visit)
Reported as:
Count of participants · Participants
Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Absence of temporal retinal vessel dragging596349
Absence of Retrolental membrane obscuring the view of the posterior pole606552
Absence of posterior retinal fold involving the macula596551
Absence of retinal detachment involving the macula606350
Absence of retinal detachment not involving the macula606250
Absence of pre-retinal fibrosis585948
Absence of optic disc pallor606552
Absence of optic disc swelling606553
Absence of pigmentary disturbance in the macula606452
Absence of atrophic changes in macula606551
SecondaryNumber of Participants With Absence of All Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit

The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula

Time frame:
at or before participant's 2 years corrected age visit (up to 2 years and 4 months post core baseline visit)
Reported as:
Count of participants · Participants
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit596147
SecondaryNumber of Participants With Absence of Individual Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit

Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula

Time frame:
at or before participant's 2 years corrected age visit (up to 2 years and 4 months post core baseline visit)
Reported as:
Count of participants · Participants
Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Absence of substantial temporal retinal vessel dragging596349
Absence of Retrolental membrane obscuring the view of the posterior pole606552
Absence of posterior retinal fold involving the macula596551
Absence of retinal detachment involving the macula606350
Absence of retinal detachment not involving the macula606250
Absence of pre-retinal fibrosis585948
Absence of optic disc pallor606553
Absence of optic disc swelling606553
Absence of pigmentary disturbance in the macula606452
Absence of atrophic changes in macula606552
SecondaryNumber of Participants With Recurrence of ROP up to 40 Weeks Post Baseline Visit in the Core Study

Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence.

Time frame:
up to 40 weeks post baseline visit in the core study
Reported as:
Count of participants · Participants
Number of Participants With Recurrence of ROP up to 40 Weeks Post Baseline Visit in the Core Study
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Recurrence of ROP up to 40 Weeks Post Baseline Visit in the Core Study192211
SecondaryNumber of Participants With Recurrence of ROP up to 52 Weeks Post Baseline Visit in the Core Study

Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence. Beyond Week 40, participants did not receive any study intervention and no new data was collected after 40 weeks post core baseline visit.

Time frame:
up to 52 weeks post baseline visit in the core study
Reported as:
Count of participants · Participants
Number of Participants With Recurrence of ROP up to 52 Weeks Post Baseline Visit in the Core Study
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Recurrence of ROP up to 52 Weeks Post Baseline Visit in the Core Study192211
SecondaryNumber of Ranibizumab Injections Received Per Participant Over the Whole Safety Observation Period

Number of ranibizumab injections received in the treatment of participants with ROP up to and including 40 weeks post baseline visit in the core study were reported.

Time frame:
up to and including 40 weeks post baseline visit in the core study
Reported as:
Mean · Number of injections
Number of Ranibizumab Injections Received Per Participant Over the Whole Safety Observation Period
Number of injectionsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Ranibizumab Injections Received Per Participant Over the Whole Safety Observation Period2.5 ± 0.962.5 ± 1.062.4 ± 0.92
SecondaryRefraction Status: Summary of Participants at Participant's 2 Years Corrected Age

Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years corrected age

Time frame:
at participant's 2 years corrected age (maximum 2 years and 4 months post core baseline visit)
Reported as:
Mean · diopters
Refraction Status: Summary of Participants at Participant's 2 Years Corrected Age
dioptersRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Best eye-0.697 ± 2.7032-0.713 ± 2.6100-1.793 ± 4.1570
Worst eye-0.825 ± 2.6575-0.829 ± 2.8346-1.516 ± 3.5652
SecondaryRefraction Status: Summary of Participants at the Participant's Fifth Birthday Visit

Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years' corrected age

Time frame:
at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Reported as:
Mean · diopters
Refraction Status: Summary of Participants at the Participant's Fifth Birthday Visit
dioptersRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Best eye-0.601 ± 2.8107-0.859 ± 2.7406-1.883 ± 4.4970
Worst eye-0.904 ± 2.8501-1.074 ± 3.0405-1.706 ± 3.5740
SecondaryChange From Baseline in Weight

Subject´s weight was reported to evaluate the physical development.

Time frame:
Baseline of the core study, at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit) and at the subjects' fifth birthday (maximum 5 years and 4 months post core baseline visit)
Reported as:
Mean · grams
Change From Baseline in Weight
gramsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Year 28695.9 ± 1406.588461.7 ± 1375.958840.6 ± 1643.80
5th Birthday14611.9 ± 3018.6514324.7 ± 2616.9614689.4 ± 3300.05
SecondaryChange From Baseline in Head Circumference

Subject´s head circumference was reported to evaluate the physical development.

Time frame:
Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Reported as:
Mean · cm
Change From Baseline in Head Circumference
cmRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Change From Baseline in Head Circumference16.5 ± 2.6016.2 ± 2.7817.2 ± 2.81
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure

Subject´s Sitting Diastolic Blood Pressure was reported to evaluate the physical development.

Time frame:
Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Reported as:
Mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure
mmHgRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Change From Baseline in Sitting Diastolic Blood Pressure16.7 ± 14.9213.6 ± 14.1016.5 ± 12.14
SecondaryChange From Baseline in Sitting Systolic Blood Pressure

Subject´s Sitting Systolic Blood Pressure was reported to evaluate the physical development.

Time frame:
Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Reported as:
Mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure
mmHgRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Change From Baseline in Sitting Systolic Blood Pressure20.6 ± 16.1316.2 ± 15.9517.6 ± 12.75
SecondaryNumber of Participants With the Summary of Respiratory Function Status

Number of participants with respiratory function status was reported

Time frame:
at the participants' fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Reported as:
Count of participants · Participants
Number of Participants With the Summary of Respiratory Function Status
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of participants with Wheezing/whistling status642
Number of participants with attacks of wheezing475045
Number of participants with frequency of sleep disturbance due to wheezing475247
Number of participants with presence of wheezing limiting child's speech ability100
Number of participants with dry cough status at night521
Number of participants with presence of smoker at home1584
SecondaryNumber of Participants With Hearing Impairment of Any Type

Number of participants with hearing function status was reported

Time frame:
at the participants' fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Reported as:
Count of participants · Participants
Number of Participants With Hearing Impairment of Any Type
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants With Hearing Impairment of Any Type224
SecondaryDuration of Hospitalization

Duration of hospitalization (from birth to first hospital discharge home) was reported to evaluate the health status of the subject

Time frame:
From baseline of the core study up to 5 years and 4 months post core baseline visit
Reported as:
Mean · days
Duration of Hospitalization
daysRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Duration of Hospitalization111.1 ± 62.27116.2 ± 78.1095.7 ± 57.07
SecondaryWeight at the Time of First Hospital Discharge

Weight (gram) at the time of first hospital discharge was reported to evaluate the health status of the subject

Time frame:
From baseline of the core study up to 5 years and 4 months post core baseline visit
Reported as:
Mean · gram
Weight at the Time of First Hospital Discharge
gramRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Weight at the Time of First Hospital Discharge2910.9 ± 1359.342966.5 ± 1198.602658.7 ± 926.92

Adverse events

Collected over throughout the study, up to approximately 5 years. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.2 mg0/61 (0%)21/61 (34.4%)41/61 (67.2%)
Ranibizumab 0.1 mg0/65 (0%)27/65 (41.5%)46/65 (70.8%)
Laser Therapy2/54 (3.7%)26/54 (48.1%)40/54 (74.1%)
Total2/180 (1.1%)74/180 (41.1%)127/180 (70.6%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventRanibizumab 0.2 mgRanibizumab 0.1 mgLaser TherapyTotal
BronchitisInfections and infestations3/613/655/5411/180
PneumoniaInfections and infestations2/614/654/5410/180
BronchiolitisInfections and infestations4/613/650/547/180
PyrexiaGeneral disorders3/611/652/546/180
DehydrationMetabolism and nutrition disorders3/610/651/544/180
VomitingGastrointestinal disorders1/613/652/546/180
Febrile convulsionNervous system disorders2/613/650/545/180
AsthmaRespiratory, thoracic and mediastinal disorders1/613/652/546/180
GastroenteritisInfections and infestations1/610/652/543/180
Respiratory syncytial virus bronchiolitisInfections and infestations1/611/652/544/180
Most frequent other events
Showing 10 of 39
Most frequent other events
EventRanibizumab 0.2 mgRanibizumab 0.1 mgLaser TherapyTotal
StrabismusEye disorders10/6112/6512/5434/180
PyrexiaGeneral disorders6/6111/6510/5427/180
NasopharyngitisInfections and infestations11/6111/659/5431/180
ConstipationGastrointestinal disorders4/618/652/5414/180
Otitis mediaInfections and infestations7/612/653/5412/180
BronchitisInfections and infestations4/614/656/5414/180
MyopiaEye disorders6/613/655/5414/180
DiarrhoeaGastrointestinal disorders3/615/655/5413/180
Gastrooesophageal reflux diseaseGastrointestinal disorders4/614/655/5413/180
PharyngitisInfections and infestations2/613/655/5410/180

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser TherapyTotal
Mean38.88 ± 7.31640.16 ± 9.83637.48 ± 8.74538.92 ± 8.739
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser TherapyTotal
Female32352794
Male29302786
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser TherapyTotal
Caucasian384032110
Black0426
Asian22181858
Native American0000
Pacific Islander0000
Unknown0000
Other1326
08

Study locations

73 sites
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Chicago, Illinois 60612, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40202, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48105, United States
  • Novartis Investigative Site
    Rochester, New York 14642, United States
  • Novartis Investigative Site
    Austin, Texas 78705, United States
  • Novartis Investigative Site
    Morgantown, West Virginia 26506, United States
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Praha 4 - Podoli, Czech Republic 14700, Czechia
  • Novartis Investigative Site
    Ostrava, Poruba 708 52, Czechia
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Koebenhavn Ø, 2100, Denmark
  • Novartis Investigative Site
    Alexandria, 21131, Egypt
  • Novartis Investigative Site
    Tallinn, 10138, Estonia
  • Novartis Investigative Site
    Amiens, 80054, France
  • Novartis Investigative Site
    Marseille, 13915, France
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Ampelokipi, GR 115 27, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 564 03, Greece
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Budapest, 1125, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380016, India
  • Novartis Investigative Site
    Mumbai, Maharashtra 400 008, India
  • Novartis Investigative Site
    Coimbatore, Tamil Nadu 641014, India
  • Novartis Investigative Site
    Madurai, Tamil Nadu 625020, India
  • Novartis Investigative Site
    Vanchiyoor, Thiruvanantapuram 695035, India
  • Novartis Investigative Site
    New Delhi, 110029, India
  • Novartis Investigative Site
    Firenze, FI 50139, Italy
  • Novartis Investigative Site
    Perugia, PG 06100, Italy
  • Novartis Investigative Site
    Fiumicino, RM 00054, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Nagoya, Aichi 453-8511, Japan
  • Novartis Investigative Site
    Nagoya, Aichi 466 8560, Japan
  • Novartis Investigative Site
    Yachiyo-city, Chiba 276-8524, Japan
  • Novartis Investigative Site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Fukuoka city, Fukuoka 814 0180, Japan
  • Novartis Investigative Site
    Kurume city, Fukuoka 830-0011, Japan
  • Novartis Investigative Site
    Sapporo-city, Hokkaido, Japan
  • Novartis Investigative Site
    Zentsuji-city, Kagawa 765-8507, Japan
  • Novartis Investigative Site
    Shimajiri-Gun, Okinawa 901-1303, Japan
  • Novartis Investigative Site
    Izumi-city, Osaka 594-1101, Japan
  • Novartis Investigative Site
    Ohtsu-city, Shiga 520-2192, Japan
  • Novartis Investigative Site
    Fuchu-city, Tokyo 183-8561, Japan
  • Novartis Investigative Site
    Ota-ku, Tokyo 143 8541, Japan
  • Novartis Investigative Site
    Setagaya-ku, Tokyo 157-8535, Japan
  • Novartis Investigative Site
    Sumida-ku, Tokyo 130-8575, Japan
  • Novartis Investigative Site
    Toshima-ku, Tokyo 170-8476, Japan
  • Novartis Investigative Site
    Kaunas, LTU LT 50161, Lithuania
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88996, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, Wilayah Persekutuan 50586, Malaysia
  • Novartis Investigative Site
    Brasov, 500025, Romania
  • Novartis Investigative Site
    Bucuresti, 020395, Romania
  • Novartis Investigative Site
    Timisoara, 300041, Romania
  • Novartis Investigative Site
    Cheboksary, 428028, Russian Federation
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Moscow, 127486, Russian Federation
  • Novartis Investigative Site
    Saint-Petersburg, 194100, Russian Federation
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Bratislava, 833 40, Slovakia
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Istanbul, Bakirkoy 34140, Turkey
  • Novartis Investigative Site
    Meselik, Eskisehir 26480, Turkey
  • Novartis Investigative Site
    Soguksu / Antalya, 07100, Turkey
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Portsmouth, PO6 3LY, United Kingdom
09

References and documents

Publications

  • Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, Weisberger A, Stiehl DP, Fleck B; RAINBOW investigators group. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health. 2021 Oct;5(10):698-707. doi: 10.1016/S2352-4642(21)00195-4. Epub 2021 Aug 13. PubMed 34391532 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Apr 2022, 70 months.

Results were first posted in Feb 2023, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2015
First posted
Dec 29, 2015
StartActual
Jun 16, 2016
Primary completionActual
Apr 21, 2022
CompletionActual
Apr 21, 2022
Results first posted
Feb 13, 2023
Last update
Feb 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02640664
Responsible party
Sponsor
First posted
Dec 29, 2015
Start date
Jun 16, 2016
Primary completion
Apr 21, 2022
Completion
Apr 21, 2022
Results posted
Feb 13, 2023
Last update
Feb 13, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion